Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 169 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location NCT ID

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

 		Schizophrenia Phase2 United States NCT07467993

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

 		Non-segmental Vitiligo Phase2 Australia
Canada
United States 		NCT07431177

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

 		Huntington Disease Phase3 Canada
United States 		NCT07326709

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

 		Geographic Atrophy Secondary to Age-related Macular Degeneration Phase2 Australia
United States 		NCT07441642

Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea

 		Hidradenitis Suppurativa, Pediatric Plaque Psoriasis, Juvenile Idiopathic Arthritis South Korea NCT07243782

Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN)

 		Metastatic Prostate Cancer China NCT07290270

A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

 		Relapsing Multiple Sclerosis Germany NCT05344469

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

 		Lymphatic Malformations Phase2, Phase3 Argentina
Australia
Belgium
France
Germany
Italy
Netherlands
Spain
Switzerland
United States
View all
 NCT05948943

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

 		Metastatic Hormone-sensitive Prostate Cancer Phase2 Australia
Brazil
Canada
China
Czechia
France
Germany
Italy
Netherlands
Poland
Singapore
South Korea
Spain
Taiwan
United States
View all
 NCT06991556

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

 		Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Phase1, Phase2 Australia
China
France
Germany
Hong Kong
Hungary
Italy
South Korea
Spain
Turkey (Türkiye)
United States
View all
 NCT07190300